logo-loader
viewAdherium

Adherium set to heat up digital health sector

au_asx2_350_55dbd59651d19.jpg

New ASX IPO listing Adherium (ASX:ADR) which numbers AstraZeneca plc (AZN) as one of its key shareholders is set for trading on the exchange on Wednesday.

Adherium's Smartinhalers attach to prescription inhalers to provide reminders and monitoring of inhaler usage.

In early August, the company had $25.8 million in signed commitments from investors including US$3 million from its commercial partner AstraZeneca as a cornerstone investor.

This has increased as applications were received in excess of the maximum subscription permitted under its Initial Public Offering prospectus of $35 milliion with the issue of 70 million shares at $0.50 per share. A total of 105,915,543 fully paid ordinary shares will be quoted.

The company’s SmartTouch device for asthmatics is approved for sale in the U.S., the EU, Australia and New Zealand. ​

The digital health company develops and manufactures solutions to monitor and increase patient adherence to prescribed therapies.

With this, it improves medication adherence for patients with chronic respiratory disease.

The first Smartinhaler was developed for use in clinical trials in 2003, and since then the company has expanded its technology platform and the product range.

Adherium now has a broad range of "smart" devices for inhaled drug delivery devices.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Adherium

Price: 0.05 AUD

ASX:ADR
Market: ASX
Market Cap: $8.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Shekel Brainweigh progresses Hitachi Europe R&D and...

Shekel Brainweigh Ltd (ASX:SBW) country manager for Australia Danny Nadri updates Proactive on progress with its signed Hitachi Europe R&D and commercial collaboration agreement.  The automation joint development and marketing agreement is for first-of-its-kind autonomous retail...

2 days, 5 hours ago

2 min read